A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors

The primary endpoint of the study was the acute GvHD incidence, the secondary endpoints were chronic GvHD incidence, overall survival (OS), transplant related mortality (TRM) incidence, relapse incidence (RI) and neutrophil and platelets engraftment after GvHD prophylaxis with ATG-CSA-MTX or PTCy-MMF-FK506

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Leukemia, Myeloid Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Neoplasms Neoplasms by Histologic Type

Sex eligibility

All sexes

Study type

Observational

Primary location

AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita

Turin, 10126, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

children and adults)
HSCT from a one-antigen mismatch unrelated donors
Treated at the Centro Trapianti Metropolitano di Torino between 2012 to 2017

Exclusion criteria

none

Treatment and study plan

No intervention

Other

no intervention, observational study

Primary outcomes

acute GvHD incidence

Time frame: 2012-2017

Sponsors and collaborators

Lead sponsor

Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna

Other

Registry information

Official study title

Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors

Important dates

Study start: 2020
Primary completion: 2021
Study completion: 2021
First posted: Oct 22, 2020
Registry last updated: Nov 26, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed